ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SCNI vs JNJ // FREE CASH FLOW YIELD

Scinai Immunotherapeutics Ltd. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SCNI 1 — JNJ 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCNI VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SCNI JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -30.00% 67.90% -97.90 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — 2.97% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) 99.20% 6.00% +93.20 SCNI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.6 62.1 -35.50 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.4M $662.49B -$662.49B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SCNI REV JNJ REV SCNI GROSS % JNJ GROSS % SCNI FCF JNJ FCF
FY 2025 $1.3M $94.19B -50.0% 67.9% -$6.1M $19.70B
FY 2024 $658.0K $88.82B -50.0% 69.1% -$6.3M $19.84B
FY 2023 $0 $85.16B — — -$9.4M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCNI // BETA —
JNJ // BETA 1.08